Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Stellantis N.V. Common Shares (STLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Stellantis N.V. Common Shares — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while Stellantis N.V. Common Shares trades at $4.26 (market cap $16.51B). The key difference: Stellantis N.V. Common Shares is far larger — about 5.8× Dyne Therapeutics Inc. Common Stock's market cap, and Stellantis N.V. Common Shares is more actively traded (28,274,156 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Stellantis N.V. Common Shares for 0 Days on average.
| DYN | STLA | |
|---|---|---|
Market Cap | $2.86B | $16.51B |
Volume | 3,341,579 | 28,274,156 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $12.12 |
52-Week Low | $14.60 | $4.27 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $2.18B | $36.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Stellantis N.V. Common Shares
Stellantis N.V. is a multinational automaker formed from the 2021 merger of Fiat Chrysler Automobiles and PSA Group, manufacturing vehicles under brands including Jeep, Ram, Chrysler, Dodge, Fiat, Peugeot, and Citroën.
Read more on STLA →
